News
$ESPR - Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic
Oct 7, 2026 · ThinkSabio Blog
$ESPR - Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
07-OCT-2026 08:00 AM ET
Share this post
💬 Comments
Loading comments…
Leave a comment
